<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="227507">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00120055</url>
  </required_header>
  <id_info>
    <org_study_id>AVALIP04</org_study_id>
    <nct_id>NCT00120055</nct_id>
  </id_info>
  <brief_title>Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo School of Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oslo School of Pharmacy</source>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether the pharmacokinetics of atorvastatin and/or
      its metabolites is altered in patients with confirmed atorvastatin-induced myopathy compared
      to healthy controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 24 hour pharmacokinetic investigation of atorvastatin and metabolites will be performed in
      15 patients with a history of atorvastatin -induced myotoxicity. The possible link to
      relevant mutations in SLCO1B1, CYP3A5 and MDR1 will be also be investigated
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date>April 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Statin toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Rechallenge test of statin induce toxicity</description>
  </primary_outcome>
  <condition>Myopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin (Lipitor)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  above 18 years

          -  previous history of atorvastatin-associated myotoxicity

        Exclusion Criteria:

          -  current treatment with drugs or herbal remedies with known pharmacokinetic
             interaction potential with atorvastatin

          -  previous CK levels above ten times the upper limit of normal range

          -  pregnancy and persistent muscular complaints after a four week wash-out period of
             statin treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Ã…sberg, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oslo School of Pharmacy</affiliation>
  </overall_official>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 2, 2014</lastchanged_date>
  <firstreceived_date>July 7, 2005</firstreceived_date>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
